|
Eden Research PLC - Oxfordshire, England-based developer of biopesticides and formulation technologies for the crop protection, animal health and consumer products industries - Announces that it has signed an agreement with Veto-pharma to supply thymol for use in bee care products. Veto-pharma is a Palaiseau, France-based animal health pharmaceutical laboratory with a dedicated research centre focused on bee health, and intends to use the thymol in its varroa mite treatment for bee hives. Eden notes that thymol is one of the three active ingredients in Eden’s suite of biopesticide products and is currently registered in the EU and the US. Chief Executive Officer Sean Smith comments: ‘We are always looking for opportunities to leverage our existing registrations and technologies to diversify our product portfolio and revenue streams. This represents a meaningful contribution to that strategy, while also enhancing the return on investments made in active ingredient dossiers across the EU, the US, and other markets. We are pleased to be working with our new partner, Veto-pharma and supporting them in making their product a great success. We anticipate there will be additional opportunities in the future to further expand this relationship.’ Current stock price: 2.75 pence, down 5.3% on Friday afternoon in London 12-month change: down 46% Copyright 2025 Alliance News Ltd. All Rights Reserved
|
